vs
EXACT SCIENCES CORP（EXAS）与RH（RH）财务数据对比。点击上方公司名可切换其他公司
RH的季度营收约是EXACT SCIENCES CORP的1.0倍（$883.8M vs $878.4M），RH净利率更高（4.1% vs -9.8%，领先13.9%），EXACT SCIENCES CORP同比增速更快（23.1% vs 8.9%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $83.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 9.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
RH是美国高端家居品牌，总部位于加利福尼亚州科尔特马德拉。品牌通过线下零售门店、产品目录和线上渠道发售家居商品，截至2018年8月，在美国和加拿大共运营70家展示馆、18家全系列设计展示馆、3家婴童家居展示馆，另有36家奥莱门店。
EXAS vs RH — 直观对比
营收规模更大
RH
是对方的1.0倍
$878.4M
营收增速更快
EXAS
高出14.2%
8.9%
净利率更高
RH
高出13.9%
-9.8%
自由现金流更多
EXAS
多$37.4M
$83.0M
两年增速更快
EXAS
近两年复合增速
9.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $883.8M |
| 净利润 | $-86.0M | $36.3M |
| 毛利率 | 70.1% | 44.1% |
| 营业利润率 | -9.4% | 12.0% |
| 净利率 | -9.8% | 4.1% |
| 营收同比 | 23.1% | 8.9% |
| 净利润同比 | 90.1% | 9.3% |
| 每股收益（稀释后） | $-0.45 | $1.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRH
| Q4 25 | $878.4M | $883.8M | ||
| Q3 25 | $850.7M | $899.2M | ||
| Q2 25 | $811.1M | $814.0M | ||
| Q1 25 | $706.8M | $812.4M | ||
| Q4 24 | $713.4M | $811.7M | ||
| Q3 24 | $708.7M | $829.7M | ||
| Q2 24 | $699.3M | $727.0M | ||
| Q1 24 | $637.5M | $738.3M |
净利润EXASRH
| Q4 25 | $-86.0M | $36.3M | ||
| Q3 25 | $-19.6M | $51.7M | ||
| Q2 25 | $-1.2M | $8.0M | ||
| Q1 25 | $-101.2M | $13.9M | ||
| Q4 24 | $-864.6M | $33.2M | ||
| Q3 24 | $-38.2M | $29.0M | ||
| Q2 24 | $-15.8M | $-3.6M | ||
| Q1 24 | $-110.2M | $11.4M |
毛利率EXASRH
| Q4 25 | 70.1% | 44.1% | ||
| Q3 25 | 68.6% | 45.5% | ||
| Q2 25 | 69.3% | 43.7% | ||
| Q1 25 | 70.8% | 44.7% | ||
| Q4 24 | 69.0% | 44.5% | ||
| Q3 24 | 69.4% | 45.2% | ||
| Q2 24 | 69.8% | 43.5% | ||
| Q1 24 | 70.0% | 43.5% |
营业利润率EXASRH
| Q4 25 | -9.4% | 12.0% | ||
| Q3 25 | -3.0% | 14.3% | ||
| Q2 25 | -0.3% | 6.9% | ||
| Q1 25 | -13.6% | 8.7% | ||
| Q4 24 | -122.8% | 12.5% | ||
| Q3 24 | -5.6% | 11.6% | ||
| Q2 24 | -3.8% | 7.5% | ||
| Q1 24 | -16.7% | 8.7% |
净利率EXASRH
| Q4 25 | -9.8% | 4.1% | ||
| Q3 25 | -2.3% | 5.8% | ||
| Q2 25 | -0.1% | 1.0% | ||
| Q1 25 | -14.3% | 1.7% | ||
| Q4 24 | -121.2% | 4.1% | ||
| Q3 24 | -5.4% | 3.5% | ||
| Q2 24 | -2.3% | -0.5% | ||
| Q1 24 | -17.3% | 1.5% |
每股收益（稀释后）EXASRH
| Q4 25 | $-0.45 | $1.83 | ||
| Q3 25 | $-0.10 | $2.62 | ||
| Q2 25 | $-0.01 | $0.40 | ||
| Q1 25 | $-0.54 | $0.71 | ||
| Q4 24 | $-4.69 | $1.66 | ||
| Q3 24 | $-0.21 | $1.45 | ||
| Q2 24 | $-0.09 | $-0.20 | ||
| Q1 24 | $-0.60 | $0.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $43.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.3M |
| 总资产 | $5.9B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASRH
| Q4 25 | $964.7M | $43.1M | ||
| Q3 25 | $1.0B | $34.6M | ||
| Q2 25 | $858.4M | $46.1M | ||
| Q1 25 | $786.2M | $30.4M | ||
| Q4 24 | $1.0B | $87.0M | ||
| Q3 24 | $1.0B | $78.3M | ||
| Q2 24 | $946.8M | $101.8M | ||
| Q1 24 | $652.1M | $123.7M |
股东权益EXASRH
| Q4 25 | $2.4B | $3.3M | ||
| Q3 25 | $2.5B | $-40.9M | ||
| Q2 25 | $2.5B | $-110.8M | ||
| Q1 25 | $2.4B | $-163.6M | ||
| Q4 24 | $2.4B | $-183.0M | ||
| Q3 24 | $3.2B | $-234.7M | ||
| Q2 24 | $3.2B | $-289.9M | ||
| Q1 24 | $3.1B | $-297.4M |
总资产EXASRH
| Q4 25 | $5.9B | $4.8B | ||
| Q3 25 | $5.9B | $4.7B | ||
| Q2 25 | $5.8B | $4.7B | ||
| Q1 25 | $5.7B | $4.6B | ||
| Q4 24 | $5.9B | $4.5B | ||
| Q3 24 | $6.7B | $4.4B | ||
| Q2 24 | $6.7B | $4.2B | ||
| Q1 24 | $6.4B | $4.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $131.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $83.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 9.4% |
| 资本支出强度资本支出/营收 | 3.6% | 5.5% |
| 现金转化率经营现金流/净利润 | — | 3.64× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $128.1M |
8季度趋势，按日历期对齐
经营现金流EXASRH
| Q4 25 | $151.7M | $131.9M | ||
| Q3 25 | $219.9M | $137.7M | ||
| Q2 25 | $89.0M | $86.6M | ||
| Q1 25 | $30.8M | $-18.8M | ||
| Q4 24 | $47.1M | $-31.4M | ||
| Q3 24 | $138.7M | $11.2M | ||
| Q2 24 | $107.1M | $56.1M | ||
| Q1 24 | $-82.3M | $-114.0M |
自由现金流EXASRH
| Q4 25 | $120.4M | $83.0M | ||
| Q3 25 | $190.0M | $80.7M | ||
| Q2 25 | $46.7M | $34.1M | ||
| Q1 25 | $-365.0K | $-69.7M | ||
| Q4 24 | $10.7M | $-96.0M | ||
| Q3 24 | $112.6M | $-37.9M | ||
| Q2 24 | $71.2M | $-10.1M | ||
| Q1 24 | $-120.0M | $-251.5M |
自由现金流率EXASRH
| Q4 25 | 13.7% | 9.4% | ||
| Q3 25 | 22.3% | 9.0% | ||
| Q2 25 | 5.8% | 4.2% | ||
| Q1 25 | -0.1% | -8.6% | ||
| Q4 24 | 1.5% | -11.8% | ||
| Q3 24 | 15.9% | -4.6% | ||
| Q2 24 | 10.2% | -1.4% | ||
| Q1 24 | -18.8% | -34.1% |
资本支出强度EXASRH
| Q4 25 | 3.6% | 5.5% | ||
| Q3 25 | 3.5% | 6.3% | ||
| Q2 25 | 5.2% | 6.5% | ||
| Q1 25 | 4.4% | 6.3% | ||
| Q4 24 | 5.1% | 8.0% | ||
| Q3 24 | 3.7% | 5.9% | ||
| Q2 24 | 5.1% | 9.1% | ||
| Q1 24 | 5.9% | 18.6% |
现金转化率EXASRH
| Q4 25 | — | 3.64× | ||
| Q3 25 | — | 2.66× | ||
| Q2 25 | — | 10.78× | ||
| Q1 25 | — | -1.35× | ||
| Q4 24 | — | -0.95× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -10.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RH
| RH Segment | $835.8M | 95% |
| Waterworks Segment | $48.0M | 5% |
| Gift Card And Merchandise Credit | $4.5M | 1% |
